On 20 February, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi) will publish its report for the fourth quarter and full year, 2013.
Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, at 14:00 CET. The event will be hosted by Sobi's CEO and President, Geoffrey McDonough. The presentation will be held in English.
The presentation can be followed live, or afterwards on http://www.sobi.com/. Slides used in the presentation will be made available on our website prior to the telephone conference.
To participate in the telephone conference, please call:
SE: +46 8 5199 9350
UK: +44 203 364 5372
US: +1 877 788 9023
For more information - not for publication
|Media relations||Investor relations|
|Oskar Bosson, Head of Communications||Jörgen Winroth, Vice President, Head of Investor Relations|
|T: +46 70 410 71 80||T: +46 8 697 20 00|
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within hemophilia and neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion (€ 215 M) and about 480 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.